Publisher: Bentham Science Publishers
E-ISSN: 2212-389x|4|1|1-5
ISSN: 1574-3624
Source: Current Signal Transduction Therapy, Vol.4, Iss.1, 2009-01, pp. : 1-5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Evasion of apoptosis (programmed cell death) is a hallmark of pancreatic cancer, one of the leading causes of cancer deaths in the western world. Resistance to apoptosis can promote the multistep process of tumorigenesis, since tissue homeostasis is disturbed by too little cell death. Further, defects in apoptosis programs can leads to treatment failure in pancreatic cancer, since intact apoptosis pathways are critical to mediate therapy-induced cytotoxicity. Over the last decade, the exploration of apoptosis pathways and their dysregulation in pancreatic cancer has resulted in the identification of molecular targets that can be exploited for drug development and clinical application. Such apoptosis-based cancer therapeutics open new perspectives for rationally designed treatment strategies for patients with pancreatic cancer.
Related content
Primers on Molecular Pathways – Cycling toward Pancreatic Cancer
Pancreatology, Vol. 10, Iss. 1, 2010-03 ,pp. :
Cell Death Pathways in Pancreatitis and Pancreatic Cancer
Pancreatology, Vol. 4, Iss. 6, 2004-11 ,pp. :
Primers on Molecular Pathways: Nuclear Receptors in Pancreatic Cancer
Pancreatology, Vol. 8, Iss. 4-5, 2008-08 ,pp. :
Pancreatic cancer: is combination treatment better?
By Furuse Junji
Clinical Practice, Vol. 10, Iss. 6, 2013-11 ,pp. :
Gemcitabine: Progress in the Treatment of Pancreatic Cancer
Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. :